Acute Respiratory Distress Syndrome, COVID-19
Conditions
Brief summary
This is a longitudinal, multi-center, observational study collecting diverse biological measurements and clinical and epidemiological data for the purpose of enabling a greater understanding of the onset of severe outcomes, primarily acute respiratory distress syndrome (ARDS) and/or mortality, in patients presenting to the hospital with suspicion or diagnosis of COVID-19. We seek to understand whether there are early signatures that predict progression to ARDS, mortality, and/or other comorbid conditions. The duration of the study participation is approximately 3 months.
Interventions
None listed
Sponsors
Verily Life Sciences LLC
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Participant or legally authorized representative willing and able to provide informed consent * Receiving care at a participating site * Age 18 years old or older * U.S. Resident * Confirmed positive for COVID-19 * Willing and able to comply with all study procedures
Exclusion criteria
* Self reported pregnancy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Performance (discrimination / calibration) of models | From date of study enrollment until the date of first documented ARDS diagnosis or date of death from any cause, whichever comes first, assessed up to study end (estimated at 3 months). | Performance (discrimination / calibration) of models that predict the risk of development of ARDS and/or mortality among COVID-19 patients who present to the hospital for evaluation and treatment. |
Countries
United States
Outcome results
None listed